Connecticut doctor Robert Hindes M.D., chief medical officer at Trek Therapeutics, is responsible for clinical and strategic development, and supervision of clinical operations at the organization. Robert Hindes, MD, and his team’s first task is to create an affordable therapeutic regimen to cure hepatitis C virus. While a treatment for hepatitis C already exists, the high cost of these drugs limits patient access both in the West and in developing countries. Dr. Hindes intends to address this issue by developing a cost-effective regimen which is as efficacious and safe as currently approved treatments. Trek is also exploring the development of treatments for other infectious diseases.
Dr. Hindes maintains board certification and diplomate designation with the American Board of Internal Medicine and holds certification in the subspecialty infectious disease. He completed his medical education at Rutgers Medical School in New Jersey, internal medicine residency at the Medical College of Pennsylvania Hospital, and infectious disease fellowship at Harvard Medical School and New England Deaconess Hospital.
